IPSEN (OTCMKTS:IPSEY) Shares Gap Up – Time to Buy?

IPSEN (OTCMKTS:IPSEY)’s share price gapped up prior to trading on Wednesday. The stock had previously closed at $40.00, but opened at $42.9960. IPSEN shares last traded at $42.9960, with a volume of 298 shares trading hands.

Analyst Upgrades and Downgrades

IPSEY has been the subject of several research reports. Jefferies Financial Group cut shares of IPSEN from a “hold” rating to a “moderate sell” rating in a research note on Sunday, August 2nd. Barclays raised shares of IPSEN from a “strong sell” rating to a “hold” rating in a research report on Thursday, September 17th. Finally, HC Wainwright reissued a “buy” rating on shares of IPSEN in a research report on Tuesday, June 30th. Two analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold”.

IPSEN Trading Up 5.0%

The firm has a 50-day moving average of $44.46 and a 200 day moving average of $46.11.

IPSEN Company Profile

Ipsen SA is a France-based biopharmaceutical company focused on developing and commercializing medicines for serious diseases. Its principal therapeutic areas are oncology, rare diseases and neuroscience, with operations spanning research, clinical development, manufacturing and commercial activities.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and rare endocrine conditions, Dysport (abobotulinumtoxinA) for therapeutic and aesthetic uses, and Onivyde (a liposomal formulation of irinotecan) for pancreatic cancer.